key: cord-1048346-ongpxhu5
authors: Chaudhry, Zohra S.; Williams, Jonathan D.; Vahia, Amit; Fadel, Raef; Parraga Acosta, Tommy; Prashar, Rohini; Shrivastava, Pritika; Khoury, Nadeen; Pinto Corrales, Julio; Williams, Celeste; Nagai, Shunji; Abouljoud, Marwan; Samaniego‐Picota, Milagros; Abreu‐Lanfranco, Odaliz; del Busto, Ramon; Ramesh, Mayur S.; Patel, Anita; Alangaden, George J.
title: Clinical characteristics and outcomes of COVID‐19 in solid organ transplant recipients: A case‐control study
date: 2020-07-28
journal: Am J Transplant
DOI: 10.1111/ajt.16188
sha: b0ca3597d6e0361e884155aaf13c8d9a0158abe4
doc_id: 1048346
cord_uid: ongpxhu5

Solid organ transplant recipients (SOTr) with coronavirus disease 2019 (COVID‐19) are expected to have poorer outcomes compared to nontransplant patients because of immunosuppression and comorbidities. The clinical characteristics of 47 SOTr (38 kidneys and 9 nonkidney organs) were compared to 100 consecutive hospitalized nontransplant controls. Twelve of 47 SOTr managed as outpatients were subsequently excluded from the outcome analyses to avoid potential selection bias. Chronic kidney disease (89% vs 57% P = .0007), diabetes (66% vs 33% P = .0007), and hypertension (94% vs 72% P = .006) were more common in the 35 hospitalized SOTr compared to controls. Diarrhea (54% vs 17%, P < .0001) was more frequent in SOTr. Primary composite outcome (escalation to intensive care unit, mechanical ventilation, or in‐hospital all‐cause mortality) was comparable between SOTr and controls (40% vs 48%, odds ratio [OR] 0.72 confidence interval [CI] [0.33‐1.58] P = .42), despite more comorbidities in SOTr. Acute kidney injury requiring renal replacement therapy occurred in 20% of SOTr compared to 4% of controls (OR 6 CI [1.64‐22] P = .007). Multivariate analysis demonstrated that increasing age and clinical severity were associated with mortality. Transplant status itself was not associated with mortality.

In December 2019, a cluster of patients with acute respiratory illness of unknown origin was reported from the city of Wuhan, Hubei province, China. It was determined that the causative agent was a novel coronavirus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 

The study was performed at the Henry Ford Health System (HFHS) a quaternary-care academic institution that comprises 5 hospitals in southeast and south-central Michigan. The Henry Ford Transplant Institute housed in HFHS annually performs approximately 300 organ transplants including kidney, liver, heart, lung, pancreas, intestinal, and multiorgan transplants. from March 20, 2020 through April 18, 2020, were eligible for inclusion if they were 18 years of age or older. SOT recipients managed as outpatients were subsequently excluded from the outcome analyses to avoid potential selection bias. 

This was a retrospective case-control study examining epidemiologic, laboratory, and clinical characteristics for adverse outcomes comparing SOT recipients and nontransplant controls hospitalized for COVID-19. The study was approved by the institution's institutional review board (#13739) with waiver of consent.

Both cases and controls received standard care, comprised of supplemental oxygen, high-flow nasal cannula support, mechanical ventilation, antibiotics, antiviral agents, immunomodulating medications, vasopressor support, and renal replacement therapy, as determined by the primary team.

The management of immunosuppression was at the discretion of the transplant team. In general the approach was to decrease overall immunosuppression. Typically, antimetabolites were the first to either be withdrawn or dose reduced with consideration for modification of calcineurin inhibitors (CNIs).

HFHS deployed a COVID-19 team during the time of outbreak in an effort to standardize management. Laboratory tests ordered included baseline serum C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, D-dimer, creatine phosphokinase (CPK), high-sensitivity troponin, and procalcitonin. Additionally, the protocol also defined the use of antiviral agents and adjuvant immunomodulation therapies in the treatment of patients with COVID-19.

COVID-19-positive SOT recipients and controls with moderate to severe disease as per our severity criteria along with QTc interval of <500 msec received hydroxychloroquine (HCQ) 400mg twice daily orally for the first 24 hours followed by 200mg twice a day for 4 days in patients as the antiviral agent. Adjuvant therapy included an early short course of corticosteroids (methylprednisolone 1mg/ kg in 2 divided doses for 3-7 days). 7

Data were abstracted from the electronic medical record (EMR) and recorded in a standardized electronic case report form. Data included patient demographics, clinical symptoms and signs, laboratory and radiologic results at the time of presentation. Patient data were censored on April 26, 2020.

The National Early Warning Score (NEWS) and quick sequential organ failure (qSOFA) were calculated to evaluate baseline illness severity based on vital signs obtained in the emergency department. 8 

Continuous variables were reported as median and interquartile range (IQR) and compared using the Mann-Whitney test or t test, as appropriate. Categorical data were reported as number and percentage and compared using the chi-square test or Fisher's exact t test as appropriate. No imputation was made for missing data points. The sample size was derived from all eligible consecutive hospitalized patients during the study period. A 2-sided α ≤0.05 was considered statistically significant. Bivariate and multivariable logistic regression analysis was planned a priori to test the association between the individual composite end point components and SOT status.

Clinically observed risk factors for mortality were fit a priori into a multivariate logistic regression model examining key exposures and outcomes. Survival curves were modeled using Kaplan-Meier estimation censoring data at the end of follow-up. Statistical analysis was performed using SAS 9.4 (SAS Institute, Cary, NC).

We enrolled 47 SOT recipients (cases) and 100 consecutive hospitalized nontransplant COVID-19-positive patient (controls). All patients were followed for a median duration of 35 (IQR 20-36) days or until death.

The clinical characteristics of 47 SOT recipients (38 kidneys and 9 nonkidney organs) were compared to 100 controls. Twelve of 47 SOT recipients managed as outpatients were subsequently excluded from the outcome analyses to avoid potential selection bias.

The demographics, presence of coexisting conditions, clinical symptoms, laboratory findings, and severity of illness on presentation are shown in Tables 1 and 2 . We initially compared SOT recipients with COVID-19 that were hospitalized vs those who were managed as outpatients (Table 1) . Overall 89% of all SOT recipients had undergone transplantation >1 year. Characteristics were comparable across all key demographics and coexisting conditions. Cough, fever, and shortness of breath were the most common presenting symptoms. Overall 55% of SOT recipients had diarrhea as a presenting symptom. Hospitalized SOT recipients were more likely to complain of shortness of breath compared to outpatients (68% vs 33%, P = .04). Hospitalized SOT recipients were more likely to have a lower median absolute lymphocyte counts (ALC) (0.5 vs 1.6 x 10 -9 per liter, P = .02) and abnormal chest imaging (83% vs 25%, P = .0005).

Overall, on presentation 28%, 66%, and 6% of SOT recipients were stratified as having mild, moderate, and severe disease, respectively, utilizing the HFH COVID-19 severity score. Hospitalized SOT recipients presented with a higher degree of illness severity, based on median qSOFA score (1 vs 0, P = .06), median NEWS score (6.5 vs 2, P = .0009), and HFH COVID-19 severity score.

Hospitalized SOT recipients and nontransplant patients with COVID-19 (Table 2 ) had similar demographics. SOT recipients had a higher proportion of chronic kidney disease (89% vs 57%, P = .0007), hypertension (94% vs 72%, P = .006), and diabetes mellitus (66% vs 33%, P = .0007) compared with nontransplant controls. SOT recipients were more likely to present with diarrhea (54% vs 17%, P ≤ 0.0001) and had lower median ALC (0.5 vs 0.8 x 10 -9 per liter, P = .006) and lower median hemoglobin (11.9 vs 13.3 mg/ dL, P = .04) compared to controls. SOT recipients presented with greater severity of illness as compared to controls (mean qSOFA 1.1 vs 0.7, P = .02). Using HFH COVID-19 severity score, the severity (25) .0005

Median qSOFA (IQR) 1 (0-2) 1 (0.5-2) 0 (0-0) .06

Median NEWS (IQR) 5 (3-8) 6.5 (4-9) 2 (0-4) .0009

(Continues) of illness among hospitalized transplant and nontransplant patients was comparable.

Additional subgroup analysis among kidney transplant recipients and recipients of other organs showed that demographics, clinical parameters, severity of illness at presentation, and outcomes were similar. (Table S1 ).

Laboratory parameters including serum CRP, D-dimer, ferritin, LDH, procalcitonin, and abnormal chest radiography were comparable in hospitalized SOT recipients and nontransplant controls ( Table 2) .

Immunosuppression was reduced in 70% of all SOT recipients, more often in hospitalized patients than outpatients (Table 1) .

Withdrawal or dose reduction occurred in 84%, 15%, 3%, and 2% of patients receiving antimetabolite, CNIs, mammalian target of rapamycin (mTOR) inhibitors, and belatacept, respectively. Antiviral therapy with HCQ and adjunctive therapies with corticosteroids or tocilizumab was comparable ( Table 2 ).

Overall mortality was 17% (8/47), in our transplant cohort, 23% (8/35) among those hospitalized and 58% (7/12) requiring mechanical ventilation. The primary composite outcome of ICU admission, mechanical ventilation, or death was comparable between hospitalized SOT recipients and nontransplant patients (Table 3) .

Overall, mortality between these 2 groups was comparable (23% (Figure 1 ).

Increasing HFH COVID-19 severity score was associated with greater risk of mortality, with no deaths among patients with mild disease ( Figure S1 ). Chronic lung disease 6 (17.1) 13 (13) .54

Congestive heart failure 10 (28.6) 14 (14) .05 .61

Median qSOFA (IQR) 1 (0.5-2) 1 (0-1) .02

Median NEWS (IQR) 6.5 (4-9) 6.5 (4) (5) (6) (7) (8) (9) .75

Intubated on admission -no. (%) 1 (2.9) 12 (12) .18

Direct admission to ICU -no. (%) 5 (14.3) 16 (16) .81

Mild -no. (%) 4 (11.4) 13 (13) .32

(Continues)

In our case-control study, mortality, need for ICU care, and mechanical ventilation support were comparable between COVID-19positive hospitalized SOT recipients and nontransplant controls.

Furthermore, our study demonstrates that transplant status by itself does not confer an increased risk for mortality. Additionally, we showed that our HFH COVID-19 severity score was strongly predictive of mortality.

In our transplant cohort, age >60 years and severity of COVID-19 on presentation strongly correlated with mortality, similar to what has been previously reported in the general population. 12, 13 Observational studies to date, as summarized in Of note, in our predominantly kidney transplant population, rates of AKI were high, 47%, comparable to rates of 25%-57% in other studies. [14] [15] [16] [17] 19 Of those who had AKI, about a third needed RRT, similar to previous reports. 5, 15 The high incidence of kidney injury in patients with COVID-19 may be multifactorial, including binding and Similar to other studies, fever, cough, and fatigue were the most common presenting symptoms in our entire cohort. Interestingly, diarrhea was the presenting symptom in more than half of our transplant recipients. Previous studies estimate incidence of diarrhea to range from 14% to 50% in COVID-19-positive transplant patients (Table S3) . Diarrhea may be a direct consequence of infection with SARS-CoV-2 that uses ACE2 for entry and serine protease TMPRSS2

for protein priming. Both ACE2 and TMPRSS2 are expressed in the epithelium of the small intestine. 24 Diarrhea in our kidney transplant recipients may also be due to agents such as mycophenolate.

Hospitalized transplant patients were more likely to present with severe disease and COVID-19 pneumonia characterized by shortness of breath, hypoxia, and abnormal chest X-ray on presentation.

Lymphopenia and anemia were more common among our hospital- and when compared to nonkidney transplant recipients there was no difference in presenting symptoms, comorbidities, laboratory markers, severity of disease, and mortality. However, the lack of a large cohort of nonkidney transplant limits extrapolation of these findings. Even though our median follow-up was more than 28 days, long-term outcomes such as graft function in our SOT cohort need further study.

In conclusion, hospitalized SOT recipients with COVID-19 have comparable mortality to nontransplant patients, despite a greater proportion of coexisting conditions and immune suppression.

Mortality in COVID-19-positive SOT recipients is driven by the severity of illness at presentation, independent of transplant status.

We acknowledge the entire Henry Ford Transplant Institute team for their collaborative efforts. We also acknowledge Azza Elamin MD for her help with data extraction.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of Coronavirus Disease 2019 in China: NEJM

COVID-19)

Covid-19 and Kidney Transplantation

COVID-19 in solid organ transplant recipients: a single-center case series from Spain

Early Short Course Corticosteroids in Hospitalized Patients with COVID-19

Assessment of Clinical Criteria for Sepsis

The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death

The ARDS Definition Task Force*. Acute Respiratory Distress Syndrome: The Berlin Definition

Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia

COVID-19 infection in kidney transplant recipients

Disease in Kidney Transplant Recipients in New York

Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States

Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single centre cohort of kidney recipients

COVID-19 in kidney transplant recipients

COVID-19 in solid organ transplant recipients: initial report from the US epicenter

Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10

Confirmed Cases in Wuhan, China

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve

Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management

COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Effects of chloroquine on viral infections: an old drug against todays diseases

Coronavirus disease 2019 treatment: a review of early and emerging options

Pharmacologic Treatments for Coronavirus Disease